- Home
- NLSP
as 12-20-2024 4:00pm EST
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
| Founded: | 2015 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.2M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 535.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.73 - $24.32 | Next Earning Date: | 12-31-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NLS Pharmaceutics Ltd. News
NLSP Breaking Stock News: Dive into NLSP Ticker-Specific Updates for Smart Investing
ACCESSWIRE
4 days ago
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
TipRanks
11 days ago
NLS Pharmaceutics expects to close Kadimastem merger by end of January
ACCESSWIRE
12 days ago
NLS Pharmaceutics CEO Issues Letter to Shareholders
MT Newswires
19 days ago
NLS Pharmaceutics Prices Up to $1 Million Private Placement
PR Newswire
19 days ago
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
ACCESSWIRE
20 days ago
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
ACCESSWIRE
a month ago
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
Pharmaceutical Technology
2 months ago
NLS and Kadimastem stocks soar following merger agreement
Compare NLSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NLSP NLS Pharmaceutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.